View full size
We are pleased to announce our participation in the prestigious XXXV. Izakovič Memorial 2025, which will take place on October 8–10, 2025 at the Grandhotel Praha, Tatranská Lomnica. The Izakovič Memo...
Read moreIn the spring, we will participate in the 1st Czechoslovak Congress of Medical Genetics, which will take place from April 2–4, 2025, at the Cultural and Congress Center Elektra in the spa town of Luha...
Read moreVisit us at the 19th edition of the RANK 2025 conference, which will take place on March 19th and 20th at the Zlatá Štika Hotel in Pardubice. The conference is organized by the Czech Society of Clinic...
Read more
View full size
ROS1 is a receptor tyrosine kinase of insulin receptor family. Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase gene occur in a subset of non–small-cell lung cancer (NSCLC). The ROS1 fusion partners include SLC34A2, CD74, SDC4, EZR etc. These fusions lead to constitutive kinase activity and activation of downstream pathways, such as JAK/STAT, PI3K/AKT, RAS/MAPK etc., leading to carcinogenesis. It has been reported that the presence of the ROS1 rearrangement is correlated with the efficacy of TKI therapy.Based on analysis of tumor messenger RNA, ROS1 gene fusions can be detected by real-time PCR method.
